The first chimeric antigen receptor T-cell therapy, tisagenlecleucel, received 
FDA approval for the treatment of patients up to 25 years of age with B-cell 
precursor acute lymphoblastic leukemia who haven't responded to standard therapy 
or who have relapsed at least twice.